{"entity":{"id":"cba-1535","kind":"drug","name":"CBA-1535","aka":["Tb535H"],"tldr":"CBA-1535 is an experimental trispecific T cell engager from Chiome Bioscience, in phase 1 trials for advanced solid tumours, malignant mesothelioma and small cell lung cancer and other cancers.","summary":"CBA-1535 (Tb535H) is a trispecific T cell engager (Tribody) from Chiome Bioscience. A trispecific Tribody T-cell engager with binding sites for 5T4, CD3 and 5T4; it recruits the patient's T cells and directs them to attack tumours expressing 5T4. Its furthest stage is phase 1, for advanced solid tumours, malignant mesothelioma, small cell lung cancer and non-small cell lung cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT07016997 recruiting per ClinicalTrials.gov, including a combination part with pembrolizumab. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Chiome Bioscience: chiome.co.jp","url":"https://www.chiome.co.jp/en/pipeline/"},{"label":"Chiome Bioscience: chiome.co.jp","url":"https://www.chiome.co.jp/en/pipeline/"},{"label":"Chiome Bioscience: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07016997"},{"label":"ClinicalTrials.gov: trials of CBA-1535","url":"https://clinicaltrials.gov/search?intr=CBA-1535"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["cd3"],"drugs":[],"companies":["chiome-bioscience"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07016997"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"CBA-1535","modality":"Trispecific T cell engager (Tribody)","mechanism":"A trispecific Tribody T-cell engager with binding sites for 5T4, CD3 and 5T4; it recruits the patient's T cells and directs them to attack tumours expressing 5T4.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cba-1535/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"company":[{"id":"chiome-bioscience","kind":"company","name":"Chiome Bioscience","route":"/companies/chiome-bioscience/"}],"trial":[{"id":"nct07016997","kind":"trial","name":"A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.","route":"/trials/nct07016997/"}]}}